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Autoantibodies detected after kidney transplantation
may contribute to chronic rejection. We and others have
previously described the organization of immune effectors
into functional intragraft tertiary lymphoid tissue, a site
where breakdown of B-cell tolerance may occur. To test this,
we performed a comprehensive analysis of 26 chronically
rejected kidney grafts. Antibodies were screened by indirect
immunofluorescence on HEp2 cells, a procedure that detects
antibodies to intracellular antigens, and monkey kidney
sections, which detects kidney tissue autoantigens. The
incidence of anti-HEp2 autoantibodies was significantly
higher in graft explant culture supernatants than in
patient sera. Reactivity against monkey kidney sections
was detected in almost half of culture supernatants with
anti-HEp2 autoantibodies. A local enrichment in T helper 17
and B-cell-activating factor (CD257) correlated with intragraft
production of anti-HEp2 antibodies. A decrease in Tregs and
a symmetric increase of activated OX40 (CD134)-expressing
CD4þ T cells were found in grafts in which anti-kidney
autoantibodies were produced. Thus, a stepwise breakdown
of B-cell tolerance occurs within the graft during chronic
rejection. Hence, the intragraft microenvironment interferes
with peripheral deletion of autoreactive immature B cells
that, in turn, produce antibodies against intracellular
autoantigens. When intragraft immune regulation is
insufficient, spreading of the local response against kidney
autoantigens is favored.
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Although advances in immunosuppressive therapies have
allowed a significant reduction in the incidence of acute
rejection, this progress has only marginally improved graft
life expectancy.1,2
Instead, accumulating evidence suggests that the modern
immunosuppressive armamentarium insufficiently controls
the humoral arm of the recipient’s immune response, which
has a key role in the inexorable destruction of transplanted
organs.3 Donor-specific anti-human leukocyte antigen (HLA)
antibodies are by far the most recognized category of
antibodies involved in chronic graft rejection.4 Directed
against the mismatched HLA antigens between the donor and
the recipient, they initiate rejection through complement
activation, antibody-dependent cell-mediated cytotoxicity,5,6
and direct modulation of vascular cell biology.7,8 Besides
major histocompatibility complex (MHC) antigens, non-
MHC antigens are also targeted by the recipient’s humoral
immune response, and recent evidence suggests that
these non-HLA antibodies could have a much stronger
impact on renal allograft outcome than previously thought.9
Some of the non-MHC antigenic targets expressed by the
graft are polymorphic, such as the blood group antigens
Duffy and Kidd,10 and hence they elicit a humoral allo-
immune response. In contrast, other proteins targeted by the
recipient’s humoral immune response are nonpolymorphic.
For example, antibodies against Agrin, the most abundant
heparin sulfate proteoglycan present in the glomerular basal
membrane, have been implicated in the pathogenesis of
transplant glomerulopathy.11 This implies that a breakdown
of B-cell self-tolerance accompanies chronic rejection.
Our group12–14 and others15,16 have documented the
progressive organization of inflammatory cells infiltrating
chronically rejected grafts into structures that morphologi-
cally resemble secondary lymphoid organs: tertiary lymphoid
tissue (TLT) (a process named lymphoid neogenesis).17
Lymphoid neogenesis hijacks the genetic program triggered
in the embryo during the organogenesis of canonical
secondary lymphoid tissues.18 TLT differs, however, from
canonical secondary lymphoid organs because (1) surround-
ing inflammatory cells produce huge amounts of cytokines
http://www.kidney-international.org o r ig ina l a r t i c l e
& 2012 International Society of Nephrology
Received 9 December 2010; revised 11 June 2011; accepted 12 July
2011; published online 21 September 2011
Correspondence: Olivier Thaunat, Service de Transplantation et d’Immu-
nologie Clinique, Hopital Edouard Herriot, 5 Place d’Arsonval, Lyon, France.
E-mail: olivier.thaunatpastu@free.fr
Kidney International (2012) 81, 207–219 207
and growth factors, (2) injured tissue constantly releases
neoantigens, and (3) defective lymphatic drainage traps
neoantigens and immune effectors within rejected graft.19,20
These peculiarities could interfere with the peripheral
mechanisms responsible for the maintenance of B-cell
tolerance.21,22 We therefore hypothesized that intragraft TLT
could be a major site at which breakdown of B-cell self-
tolerance occurs during chronic rejection.
RESULTS
B-cell self-tolerance breakdown correlates with chronic
rejection
The occurrence of a B-cell self-tolerance breakdown follow-
ing solid organ transplantation has been previously
reported.23–27 This phenomenon appeared to correlate with
chronic rejection. Indeed, HEp2 cell assay detected the
presence of autoantibodies in the circulation of only 3/31
(9.7%) renal transplanted patients with stable graft function,
but in 7/26 (27%) patients with terminal chronic rejection
(Figure 1). However, because the sera in the latter group were
collected late in the course of chronic rejection (that is, at
the time of renal graft explantation, when the immuno-
suppressive regimen had been tapered), it was possible that
B-cell tolerance breakdown was only an epiphenomenon
that reflected under immunosuppression. To rule out this
hypothesis, we analyzed the serum of 32 additional renal
transplanted patients at the time of the diagnosis of chronic
rejection. We found that the incidence of circulating anti-
HEp2 autoantibodies was similar in the two cohorts of
patients with chronic rejection (7/26: 27% vs. 10/32: 31%;
P¼ 0.72; Figure 1) and therefore independent of the timing
of the analysis.
Tertiary lymphoid tissue develops within chronically
rejected grafts
Control renal tissues, obtained from the intact portion of
six kidneys removed for cancer, were devoid of interstitial
inflammation (Figure 2a).
In contrast, inflammatory infiltrates were detected in the
interstitium of all 26 renal grafts removed for terminal
chronic rejection. In the vast majority of explanted kidneys
(EKs; 24/26, 92%), most of the immune cells (490%) were
grouped, conferring a nodular organization to the infiltrate
(Figure 2a). These nodules exhibited a highly organized
microarchitecture with clear cell subset segregation: the core
of the B cells was surrounded by T cells and mature dendritic
cells (Figure 2a). As in canonical secondary lymphoid
organs, the compartmentalization of the different cell subsets
appeared to be mediated by gradients of homeostatic
chemokines CCL21 (in the T-cell area) and CXCL13 (in the
B-cell area; Figure 2b). Furthermore, neolymphatic vessels
and peripheral lymph node addressin-expressing high
endothelial venules were observed in the periphery of the
nodules (Figure 2a).
Because their spatial organization was highly reminiscent
of secondary lymphoid organs, these lymphoid structures
have been named TLT. Interestingly, almost all CD138-
expressing plasma cells were found within or in close vicinity
to TLTs (Figure 2a), suggesting that part of these cells
differentiated locally, as previously reported.18
The graft is a major site of B-cell self-tolerance breakdown
during chronic rejection
We hypothesized that intragraft TLT could be a site of B-cell
self-tolerance breakdown during chronic rejection. To test
this hypothesis, paired comparisons between sera (assuming
that they reflect the repertoire of the humoral responses
elicited in the canonical secondary lymphoid organs: spleen
and lymph nodes) and explanted kidney culture supernatants
were made. The incidence of anti-HEp2 autoantibody was
significantly higher in EK culture supernatant than in serum
(19/26: 73% vs. 7/26: 27%; P¼ 0.0009; Table 1 and Figure 1).
None of the pairs of samples were positive in the serum
and negative in the EK culture supernatant. In contrast,
autoantibodies were exclusively detected in EK culture
supernatants for 12 pairs (Table 1). Additional autoantibody
specificities, present in the EK culture supernatant but not in
the serum, were detected in four of the seven pairs for which
both the serum and the EK culture supernatant were positive
(EK5, EK10, EK14, and EK16; Table 1). These results strongly
suggest that the graft is a major site of B-cell self-tolerance
breakdown during chronic rejection.
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Figure 1 |Chronic rejection (CR) correlates with B-cell
tolerance breakdown. The incidence of anti-HEp2 cell
autoantibodies was evaluated in sera and explanted kidney (EK)
graft culture supernatants. Sera were collected from renal
transplanted patients (1) without chronic rejection (white bar),
(2) at diagnosis of chronic rejection (gray bar), and (3) at renal
graft explantation (black bars). No CR versus CR: *Po0.05.
Incidence of anti-HEp2 cell autoantibodies was higher in EK graft
culture supernatants than in sera (***Po0.001).
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Analysis of the autoantigen repertoire targeted by the
recipient immune system
Indirect immunofluorescence is currently the standard
technique for autoantibody detection in clinical labora-
tories.28 Epithelial cell line HEp2 was used as the substrate for
the detection of autoantibodies directed against intracellular
antigens and organ frozen sections for the screening of tissue-
specific autoantibodies.29
Out of the 26 EK culture supernatants, only 7 (27%) were
devoid of detectable autoreactivity (Table 1 and Figure 1).
Intracellular autoantigens were more frequently targeted
by the recipient’s humoral response than tissue-specific
autoantigens (19/26¼ 73% vs. 9/26¼ 35%; P¼ 0.005).
Anticytoplasmic and antinuclear antibodies were detected
with similar incidence (Table 1 and Figure 3).
Rat sections of kidney, stomach, and liver were used to
screen EK culture supernatants for the presence of tissue-
specific autoantibodies. Interestingly, only reactivity against
the chronically rejected tissue (that is, kidney) was detected
in 9/26 (35%) samples (Figure 3). Comparable staining
patterns were observed when the supernatants were tested on
monkey kidney frozen sections (Table 1 and Figure 3), ruling
out the possibility that the binding to kidney frozen sections
was due to anti-rodent xenoreactivity.
Indirect immunofluorescence technique did not allow us
to identify the kidney-specific protein(s) targeted by the
recipient immune system during chronic rejection. However,
all the nine positive samples displayed a diffuse homogenous
staining of tubular epithelial cells, which was more
pronounced for distal tubules in the case of EK12 (Figure 3).
Additional staining of the basal membrane of distal tubules
was noted for EK2 (Figure 3).
Strikingly, all EK culture supernatants with anti-kidney
reactivity also contained antibodies directed against intracel-
lular autoantigens (Table 1). On the basis of the profile of
autoreactivity, it was therefore possible to split the cohort
into three groups: chronically rejected grafts in which no
autoantibodies were produced (group autoI–; n¼ 7); chroni-
cally rejected grafts in which only anti-HEp2 antibodies were
detected (group non-kid spec; n¼ 10); and finally chronically
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Figure 2 | Tertiary lymphoid tissue (TLT) develops within chronically rejected grafts. Systematic histological analysis was carried out on
sections of 26 kidney grafts, explanted because of terminal chronic rejection, and in 6 normal kidneys. (a) Hematoxylin–eosin–safran (HES)
staining showed (1) the absence of interstitial inflammation in normal kidneys, and (2) the nodular organization of immune effectors
infiltrating chronically rejected grafts (original magnification  50). The spatial organization of cell populations was analyzed by
immunohistochemistry with antibodies (Abs) directed to CD20 (B cells), CD3 (T cells), dendritic cell-lysosomal-associated membrane protein
(DC-LAMP; mature dendritic cells), and CD138 (plasma cells). Black dashed line indicates the lymphoid nodule boundary. Peripheral lymph
node addressin (PNAd) and podoplanin immunostaining revealed the high endothelial venules and lymphatic networks, respectively,
surrounding the nodules (original magnification  100). (b) Immunohistochemistry revealed the production of homeostatic chemokines
CXCL13 (chemokine (C-X-C motif) ligand 13) and CCL21 (chemokine (C-C motif) ligand 21) in lymphoid nodules. Endothelial cells of the
vessels located in the outer boundary of the nodules stained positively for CCL21, which attracts T cells and mature dendritic cells.
In contrast, B-cell-attracting chemokine CXCL13 was exclusively detected in the center of the nodules (original magnification  100).
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rejected grafts in which both anti-HEp2 and anti-kidney
antibodies were detected (group kidney spec; n¼ 9). The
clinical characteristics of the three groups of patients were
not significantly different (Table 2). The size of interstitial
inflammatory infiltrate (Banff i score) was similar in the three
groups (Figure 4a), as were the percentages of B cells and
plasma cells infiltrating the grafts (Figure 4b). These data rule
out the possibility that the intensity of local autoimmune
response merely reflects the ability to recruit B cells within
chronically rejected graft.
Inflammatory cytokine microenvironment promotes B-cell
tolerance breakdown
Cytokine network alteration has been recurrently proposed as
a cause for immunoregulatory disorders and autoreactivity.
In an attempt to gain insights into the mechanisms respon-
sible for the occurrence of intragraft B-cell tolerance break-
down during chronic rejection, we analyzed the cytokine
microenvironment in EKs.
The concentrations of inflammatory cytokines tumor
necrosis factor-a, interleukin (IL)-1b, and IL-6 were similar
in the culture supernatants of the three groups (Figure 5a,
upper panel). In contrast, there was a twofold increase in the
level of transforming growth factor-b in non-kid spec and
kidney spec EKs (autoI-¼ 511±65 pg/ml, non-kid spec¼
1149±90 pg/ml, and kidney spec¼ 1063±230 pg/ml;
P¼ 0.04), creating the optimal conditions for local T helper
17 (Th17) differentiation. Indeed, a combination of trans-
forming growth factor-b plus IL-6 or IL-1b is essential for
initial differentiation of the Th17 subset, which has been
Table 1 | Repertoire of auto- and allo-antibodies in sera and EK culture supernatants
Sera EK culture supernatants
Anti-HEp2 Ab Anti-monkey kidney Ab Anti-HLA Ab
EK1 3 (A2, A26, A32, A68, A69)
EK2 Homogeneous nuclear
Centromere
Diffuse homogeneous on tubular cells
Distal tubular basal membrane
1 (A3, A11, A26, B59, B67)
EK3 Nucleolar Diffuse homogeneous on tubular cells 1 (A2, A68, DR7)
EK4 Fine granular cytoplasmic 1.3 (DQ2, DQ3, DQ4, DR8)
EK5 Homogeneous nuclear
Nucleolar
Nucleolar
Fine granular cytoplasmic
1 (DR3, DR7)
EK6 Cytoskeletal
EK7 2.5 (A25, A26, A34, A66, DR13)
EK8 Fine granular cytoplasmic
EK9 Cytoskeletal 6.4 (32 specificities)
EK10 Nucleolar Nucleolar
Fine granular cytoplasmic
Diffuse homogeneous on tubular cells 19.3 (58 specificities)
EK11 Fine granular cytoplasmic 0.5 (B35, DR1)
EK12 Nucleolar Diffuse homogeneous on tubular cells (distal++) 1 (B51)
EK13
EK14 Homogeneous nuclear Fine granular cytoplasmic ND
EK15 1 (DQ1, DQ5, DQ6)
EK16 Homogeneous nuclear Homogeneous nuclear
Fine granular cytoplasmic
Diffuse homogeneous on tubular cells 2.6 (13 specificities)
EK17 Mitochondrial Mitochondrial Diffuse homogeneous on tubular cells 0.2 (DQ5)
EK18 Homogeneous nuclear
Nucleolar
Mitochondrial
Diffuse homogeneous on tubular cells 1.2 (B12, B21, B44, B45, B49, B50)
EK19 ND
EK20 Cytoskeletal ND
EK21
EK22 Nucleolar
Fine granular cytoplasmic
EK23 Homogeneous nuclear
Nucleolar
Mitochondrial
Nucleolar
Mitochondrial
Diffuse homogeneous on tubular cells
EK24 Homogeneous nuclear
Nucleolar
Homogeneous nuclear
Nucleolar
EK25 Homogeneous nuclear
Nucleolar
Fine granular cytoplasmic
Diffuse homogeneous on tubular cells 5 (25 specificities)
EK26
Abbreviations: Ab, antibody; EK, explanted kidney; HLA, human leukocyte antigen; ND, not done.
Epithelial cell line HEp2 was used as the substrate for the detection of autoantibodies directed against intracellular antigens and kidney frozen sections for the screening of
tissue-specific autoantibodies. The 26 samples were split into three groups according to the pattern of autoimmune reactivity: (1) no autoantibodies (group autoI–; white),
(2) only anti-HEp2 antibodies (group non-kid spec; gray), and (3) both anti-HEp2 and anti-kidney antibodies (group kidney spec; dark gray). Anti-Hep2 specificities detected
only in the serum or the culture supernatant of a pair are indicated in bold.
Anti-class I and class II HLA antibodies were sought for in EK culture supernatants by luminex assay. The diversity of the alloimmune response was calculated as the number of
detected specificities normalized by the number of HLA mismatches for the donor/recipient pair.
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shown to have a central role in the pathogenesis of
inflammation and autoimmunity.30 Accordingly, IL-17 and
IL-21, the two cytokines produced by Th17 cells and known
to promote the development of autoreactive B cells,31,32 were
only detectable in culture supernatants of non-kid spec and
kidney spec EKs (Figure 5a, lower panel).
The comparable levels of interferon-g and IL-4 suggest
that there was no additional bias in cytokine microenviron-
ment polarization between the three groups (Figure 5a, lower
panel).
A recent report has suggested that the combination of
IL-17 and B-cell-activating factor (BAFF, CD257) could be
particularly efficient in protecting B cells from apoptosis and
promoting their proliferation and differentiation into plasma
cells.31 As compared with normal kidney tissue, the level
of expression of BAFF was significantly increased in all EKs
(Figure 5b, left panel). This augmentation was, however,
significantly more pronounced in the two groups in which
autoantibodies were detected (autoI-¼ 0.62±0.02 vs. non-
kid spec¼ 0.70±0.03 and kid spec¼ 0.70±0.02; P¼ 0.03);
in these groups, BAFF expression was even higher than in
canonical secondary lymphoid organs (Figure 5b, left panel).
Immunohistochemical stainings of EK sections validated
these results at the protein level and demonstrated that
virtually all cells of the inflammatory infiltrate produced
BAFF (Figure 5b, right panel).
Defective immune regulation correlates with tissue-specific
tolerance breakdown
Autoantibodies directed against kidney-specific antigens were
detected only in a fraction (9/26, 35%) of culture super-
natants (Table 1). Strikingly, all EK culture supernatants with
anti-kidney reactivity also contained antibodies directed
against intracellular autoantigens. These data indicate that
B-cell self-tolerance breakdown is a stepwise process during
chronic rejection: starting with intracellular antigen targets,
the recipient’s humoral autoimmune response can spread to
tissue-specific antigens.
Because no difference was found between non-kid and
kidney spec groups regarding the concentrations of IL-17 and
IL-21 (Figure 5a), and the level of expression of BAFF (Figure
5b), we concluded that the occurrence of tissue-specific
tolerance breakdown was unlikely to be the mere conse-
quence of an increased local inflammation, but was rather
controlled by molecular determinants that remained to be
identified.
We have recently reported that in a murine experimental
model of chronic rejection, intragraft TLT sometimes displays
defective T-cell immune regulation.33 To test whether this
mechanism could be responsible for the development of anti-
kidney B-cell clones, the composition of T-cell infiltrate was
analyzed by flow cytometry in cell suspensions obtained from
EKs. Although the percentage of CD3þ T cells was similar in
HEp2
Crl–
Crl–
Monkey kidney
Monkey kidney
EK
23
R
ep
re
se
nt
at
ive
 e
xa
m
pl
es
EK
 c
ul
tu
re
 s
up
er
n
a
ta
nt
s
Rat kidney Rat liver Rat stomach
Figure 3 |Repertoire of autoantigens targeted by recipient’s immune system. Explanted kidney (EK) culture supernatants were
screened for the presence of autoantibodies by indirect immunofluorescence. Negative controls and representative findings are shown.
(Upper row) HEp2 cells are routinely used to detect antibodies against intracellular autoantigens. Distinct patterns of fluorescence,
sometimes present simultaneously, indicate different autoantibody specificities. The most frequently observed were homogenous nuclear
(second and third thumbnails), nucleolar (second and fourth thumbnails), and cytoplasmic (third and fourth thumbnails). (Middle row)
Monkey kidney frozen sections were used to detect antibodies directed against kidney autoantigens. The second thumbnail is an example
of the most frequently observed pattern: diffuse homogenous fluorescence of tubular cells. The third thumbnail shows an additional
reactivity against distal tubular basal membrane. In the fourth thumbnail, the fluorescence of tubular cells is increased for distal tubules.
(Lower row) Rat sections of kidney, stomach, and liver were used to detect antibodies directed against tissue-specific autoantigens. No
reactivity was noted against stomach and liver tissues. Some EK culture supernatants (that is, EK23) showed reactivity against rat kidney. The
pattern of fluorescence was as follows: a diffuse homogenous fluorescence of tubular cells was superimposable to that observed against
monkey kidney frozen section.
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the three groups, the proportion of memory T cells, which
are less sensitive to the suppressive effect of regulatory
T cells (Tregs),34,35 was increased in non-kid spec and kidney
spec groups (Figure 6a). Furthermore, a two-third reduction
in the percentage of CD3þ CD4þ CD25bright Foxp3þ
Tregs was observed in the kidney spec group (non-kid
spec¼ 6.53±1.52% vs. kidney spec¼ 1.98±0.76%; P¼ 0.03;
Figure 6b). Finally, the proportion of T-helper cells express-
ing OX40 (CD134), a member of the tumor necrosis factor
receptor family able to enhance the production of auto-
antibodies and block the induction of Tregs,36 was increased
15-fold in the kidney spec group (non-kid spec¼ 0.22±
0.08% vs. kidney spec¼ 3.24±0.84%; Po0.0001; Figure 6c).
Relationship between alloimmune and autoimmune
intragraft humoral responses
We have recently reported that TLTs within chronically
rejected human renal grafts are the sites of production
of alloantibodies.18,37 Interestingly, Th17 cytokines38 and
BAFF37 have both been shown to promote the development
of intragraft humoral alloimmune response. Furthermore,
defective local immune regulation correlated with the
production of a wider repertoire of anti-HLA antibodies
in TLT.33 Because the same mechanisms seem to be involved
in intragraft B-cell tolerance breakdown, we were keen to
analyze the relationship between alloimmune and auto-
immune intragraft humoral responses.
Luminex assay detected anti-HLA antibodies in 15/23
(65%) EK culture supernatants tested (Table 1).
Anti-HLA alloantibodies were detected with comparable
frequencies in culture supernatants of the autoI-, non-kid
spec, and kidney spec groups (3/6 vs. 4/8 vs. 8/9; P¼ 0.16).
Trends for higher incidence and more diverse repertoire were
observed for the kidney spec group, but the differences did
not reach the level of statistical significance (Figure 7).
The absence of direct correlation between alloimmune and
autoimmune reactivity in culture supernatants could either
be due to the limited number of samples analyzed or be an
indication that the pathophysiology of the two local humoral
responses are not strictly superimposable.
Table 2 | Clinical characteristics of the population studied
Transplantation
Characteristics of
the donor
Characteristics of
the recipient
Immunosuppressive
regimen
Biopsy-proven
rejection episodes
Age/
gender
Donor
type
Age/
gender
Cause
of ESRF
HLA
mismatch
Rank
of Tr Induction Maintenance Nb
Date (day post Tr)/
Banff score
EK1 35/M C 24/M Uropathy 1A, 1B, 1DR 2 OKT3 CS, Aza, Csa 0
EK2 17/M C 40/F FSGS 1A, 2B, 2DR 1 ATG CS, Aza, FK506 0
EK3 46/F C 22/M Uropathy 1A, 1B, 2DR 1 Anti-CD7 CS, Aza, Csa 1 16/IA
EK4 55/M C 27/F Uropathy 2B, 2DR 1 CS, MMF, FK506 1 1558/IA
EK5 16/F C 7/M HUS 2B 2 CS, Aza, Csa 1 5790/act CR
EK6 41/F C 36/M IgA N 1A, 2B, 2DR 1 Anti-IL2R CS, MMF, Csa 1 45/borderline
EK7 52/M L 27/M Cort Nec 1A, 1B 2 Anti-IL2R CS, MMF, FK506 6 1404-1586/IBa
EK8 59/F C 55/M NAS 2A, 1B, 1DR 1 CS, Csa, mTOR 1 56/IA
EK9 57/F C 25/F Uropathy 2A, 1B, 1DR 1 Anti-IL2R CS, MMF, FK506 1 38/IA
EK10 49/M L 18/M Uropathy 1A, 1B, 2DR 2 CS, Aza, Csa 2 1660/act CR; 2901/act CR
EK11 54/F C 27/M HUS 1A, 1B 2 ATG CS, MMF, FK506 0
EK12 61/M C 35/M ADPKD 1A, 1B, 2DR 1 Anti-IL2R CS, MMF, FK506 1 73/IA
EK13 62/M C 56/M FSGS 2DR 1 Anti-IL2R CS, MMF, Csa 0
EK14 46/M C 35/F FSGS 1A, 2B, 1DR 2 ATG CS, Aza, Csa 0
EK15 53/F C 55/F IgA N 1A, 2B 3 ATG CS, MMF, FK506 2 835/IA; 1121/IA
EK16 3/M C 36/F Uropathy 2A, 1B, 1DR 1 OKT3 CS, Aza, Csa 0
EK17 73/M C 63/M Unknown 1A, 1B, 1DR 1 ATG CS, MMF, FK506 0
EK18 57/F C 32/M Unknown 1A, 2B, 2DR 1 Anti-IL2R CS, MMF, Csa 1 540/IB
EK19 45/M C 56/M IgA N 1A, 2B, 1DR 1 CS, MMF, Csa 0
EK20 32/F C 46/M ADPKD 2A, 2B, 1DR 1 Anti-IL2R CS, MMF, mTOR 1 132/IA
EK21 62/M C 56/M NAS 1A, 1B, 2DR 1 CS, MMF, FK506 0
EK22 18/M C 40/F Alport Sd 2A, 1B, 2DR 1 CS, MMF, FK506 0
EK23 59/M C 24/M HUS 1A, 1B, 1DR 1 Anti-IL2R CS, MMF, Csa 0
EK24 79/M C 71/F ADPKD 1A, 2B, 1DR 1 Anti-IL2R CS, MMF, FK506 0
EK25 34/M C 20/M Unknown 1A, 2B, 1DR 1 CS, Csa, mTOR 1 12/IA
EK26 19/F C 23/M Goodpasture 2A, 1B, 2DR 1 ATG CS, MMF, FK506 0
Abbreviations: act CR, active chronic rejection; ADPKD, autosomal dominant polycystic kidney disease; Alport Sd, Alport syndrome; Anti-IL2R, anti-interleukin 2 receptor; ATG,
antithymocyte globulin; Aza, azathioprine; Cort Nec, cortical necrosis; CS, corticosteroid; Csa, cyclosporine A; EK, explanted kidney; ESRF, end-stage renal failure; F, female;
FK506, tacrolimus; FSGS, focal segmental glomerulosclerosis; HUS, hemolytic and uremic syndrome; IgA N, IgA nephropathy; M, male; MMF, mycophenolate mofetil; mTOR,
inhibitor of mammalian target of rapamycin; NAS, nephroangiosclerosis; OKT3, anti-gCD3 antibodies; Rank of Tr, rank of transplantation.
aEK7 underwent a cortico-resistant rejection episode that persist on six consecutive biopsies despite treatment. The dates of the first and last biopsies are indicated as well as
the higher Banff score.
The 26 patients were split into three groups according to the pattern of autoimmune reactivity detected in explanted graft culture supernatants: (1) no autoantibodies (group
autoI–; white), (2) only anti-HEp2 antibodies (group non-kid spec; gray), and (3) both anti-HEp2 and anti-kidney antibodies (group kidney spec; dark gray).
Color code allows the identification of the groups: white, patients from autoI– group; gray, patients from non-kid spec group; dark gray, patients from kidney spec group.
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DISCUSSION
Over the past decade, accumulating evidence has demon-
strated that in addition to provoking alloimmune responses,
allografts can also trigger humoral responses directed against
self.23–27 In the current study, circulating autoantibodies were
indeed detected in one-third renal transplant recipients
diagnosed with terminal chronic rejection, an incidence
similar to that reported in previously published works.
The presence of autoantibodies implies that the recipient’s
immune system fails to control the emergence of autoreactive
B-cell clones. The site and the mechanisms responsible for
this anomaly, however, remained elusive.
Recent studies12–16 have demonstrated that during chronic
rejection, inflammatory infiltrate tends to organize progres-
sively within the graft into ectopic TLT. Several clues point
toward TLT as a potential site for self-tolerance breakdown
during chronic rejection. TLT indeed is present in an
inflammatory microenvironment37,38 and is constantly fed
by neo-antigens released by rejected tissue and trapped by
defective lymphatic drainage.19,20 Moreover, comparing the
immune responses elicited against donor–recipient mis-
matched HLA antigens in intragraft TLT and in canonical
secondary lymphoid organs, we found that the repertoire of
anti-HLA antibodies produced in TLTwere more diverse,18,33
indicating that the selection of the B-cell clones could be
more lax in this ‘non-professional’ lymphoid tissue. To
further test this theory, we conducted tissue culture experi-
ments of chronically rejected kidneys, and compared the
incidence of intragraft-produced autoantibodies with the
incidence of serum autoantibodies. Autoantibodies were
found in 77% of chronically rejected graft culture super-
natants, and the graft appeared to be the sole possible source
of autoantibodies for 55% of the patients.
We are fully aware of the limits of our experimental
setting. First, because antibodies produced in canonical
secondary lymphoid organs reach the graft through the
circulation, we assumed that serum reflects humoral
responses of spleen and lymph nodes. However, we cannot
exclude the fact that a part of the antibodies produced within
the graft also passed in the circulation. It is noteworthy to
state that although this phenomenon would lead to an
overestimation of the contribution of canonical secondary
lymphoid organs, it would not alter our main conclusion that
the graft is a major site of B-cell self-tolerance breakdown
during chronic rejection. Another limitation of the study is
that we did not perform TLT microdissection. It is therefore
impossible to conclude whether autoantibodies and cytokines
measured in EK culture supernatants were produced in TLT
or by interstitial cells located outside the nodules. Regarding
this issue, it is important to keep in mind that histological
analyses showed that the vast majority (490%) of the
cells infiltrating EK were packed, and that almost all the
CD138þ plasma cells were found within or in close vicinity
to the nodules, a finding in line with previously published
works.18,39,40 It is therefore tempting to speculate that
B-cell tolerance breakdown takes place in intragraft TLT
during chronic rejection. Finally, in contrast with recently
published works,41,42 we did not use high-density protein
microarrays, which make screening for antibodies against
thousands of proteins feasible, and were therefore unable to
precisely identify which autoantigen(s) were targeted by the
recipient’s immune system. Instead, indirect immuno-
fluorescence on HEp2 cells and monkey kidney sections
established that (1) autoantibodies produced in TLT were
mostly directed against intracellular proteins, and (2) only a
limited fraction of the patients (35%) had reactivity against
kidney antigens. Interestingly, all the patients with anti-
kidney autoantibodies also displayed reactivity against
intracellular autoantigens, suggesting that B-cell self-toler-
ance breakdown could be a stepwise process that starts with
intracellular antigens and sometimes extends to tissue-
specific antigens.
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Physiologically, developing B cells are first tested for self-
tolerance in the bone marrow after expression of the newly
arranged B-cell antigen receptor (BCR) on the cell surface.
Cells that encounter self-antigen are either deleted, undergo
receptor editing, or become anergic, depending on the
affinity and the physical form of the antigen encountered.43,44
Despite these central tolerance mechanisms,B40% of newly
formed B cells entering the periphery are self-reactive (mainly
against intracellular antigens) and additional tolerance
checkpoints must operate in the spleen as immature B cells
become naive mature B cells.45 This progressive decline in
self-reactive cells fails to occur in patients with rheumatoid
arthritis,46 a disease in which the presence of TLT within
inflamed synovial tissue has been recurrently reported.47,48
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These findings support the conclusions that (1) peripheral
selection is essential for maintaining B-cell self-tolerance
and (2) TLT could interfere with this process. Immature
transitional B cells are exquisitely sensitive to BCR cross-
linking-induced apoptosis,49 which facilitates negative selec-
tion to self-antigens that are not expressed in the bone
marrow compartment. Rejection causes the release of
formerly sequestered autoantigens, which are immediately
accessible to the immune effectors in TLT. One would
therefore expect an efficient peripheral deletion of auto-
reactive immature B cells in TLT. However, although BCR
specificity is important in determining whether an individual
B cell survives the transitional ‘bottleneck’, responses to key
environmental signals, such as cytokines, also significantly
contribute to determining B-cell fate. Interestingly, EKs in
which autoantibodies were produced were characterized by
increased levels of transforming growth factor-b, a cytokine
that combines with IL-1b and IL-6 to create the optimal
conditions for Th17 differentiation. Th17 cells in turn
enriched the TLT microenvironment in IL-17 and IL-21.
The finding that an excess of Th17 cytokines can promote
humoral autoimmunity is in line with recent evidence
obtained in both experimental models50,51 and in lupus
patients.31
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Inflammatory cells infiltrating chronically rejected grafts
produced a huge amount of BAFF (CD257),37 a molecule
known to have a critical role in peripheral B-cell tolerance.
This prosurvival cytokine is indeed necessary for B-cell
survival and differentiation beyond the late transitional
stage,52 and competition for limiting levels of BAFF has
been shown to favor self-tolerant B cells during peripheral
B-cell development.53,54 In lupus patients, Doreau et al.31
have recently reported that IL-17 functioned in synergy with
BAFF to protect autoreactive B cells from BCR-mediated
apoptosis and sustain their differentiation into autoantibody-
secreting cells. In accordance with these data, an increased
level of BAFF was observed in chronically rejected grafts in
which B-cell tolerance breakdown occurred.
Although increased levels of Th17 cytokines and BAFF in
TLT were sufficient to promote the local production of
antibodies directed against intracellular autoantigens, our
data suggest that additional mechanisms were required for
the self-tolerance breakdown to extend to kidney-specific
autoantigens. Comparing intragraft TLT and canonical
secondary lymphoid organs in a murine experimental model
of chronic rejection, we recently observed that immune
regulatory mechanisms were flawed in TLT.33 We hypothe-
sized that this defect could synergize with the inflammatory
cytokine microenvironment to promote the spreading of
B-cell tolerance breakdown in TLT. In line with this hypo-
thesis, we found that the two groups of EKs in which
autoantibodies were produced were infiltrated by an
increased proportion of memory T-cell subsets, which are
less sensitive to the suppressive effect of Tregs.34,35 Further-
more, the percentage of Tregs in EKs from the anti-kidney
spec group was only one-third of the other two groups.
Finally, EKs from anti-kidney spec group were also charac-
terized by a massive increase in the percentage of OX40-
expressing CD4þ T cells. The cell surface glycoprotein OX40
(CD134) is a member of tumor necrosis factor receptor
family that binds to its partner OX40L (CD252) at the surface
of professional antigen-presenting cells and activated B
cells.36 OX40–OX40L interactions enhance ongoing immune
response by imparting division and survival signals to T cells
and by blocking the induction of Tregs.36 These results,
together with recent animal studies that have shown that
excessive OX40–OX40L interactions lead to spontaneous
autoimmune manifestations,55 suggest that T cells expressing
OX40 contribute to the emergence of anti-kidney auto-
reactive B-cell clones in TLT, both directly and through the
blockade of local immune regulatory mechanisms.
Conclusion
We conclude that B-cell tolerance breakdown associated with
chronic rejection takes place preferentially within the graft
and seems to be a stepwise process. Rejection causes the
release of formerly sequestered autoantigens, which are
immediately accessible for the immune effectors in TLT.
BCR ligation of immature B-cell clones should induce their
deletion; however, because the microenvironment of this
non-canonical lymphoid tissue is invariably enriched in Th17
cytokines and BAFF, autoreactive B cells are protected from
peripheral deletion and differentiate into plasma cells. This
first step results in local production of antibodies directed
against intracellular autoantigens. The emergence of tissue-
specific autoreactive B-cell clones appears to require the
additional failure of local immune regulatory mechanisms,
possibly due to OX40-expressing CD4þ T cells.
MATERIALS AND METHODS
Human samples
Explanted renal grafts. A total of 31 human renal allografts,
explanted for terminal chronic rejection (EKs), were collected in five
transplantation centers over a period of 5 years. Among them, three
were discarded because they were explanted after anti-CD20
antibody administration and two because the recipient had a past
medical history of autoimmune disease (lupus). Therefore, 26 EKs
were considered in the present study. The tissues were maintained
in germ-free conditions at 4 1C and were processed o24 h after
explantation. Serum was obtained from the patients on the day of
the explantation. The individual characteristics of the 26 patients are
presented in Table 2.
Additional serum samples. Serum samples are routinely
collected at each annual visit for all transplanted patients followed
up in our center. Additional sera used in the study were retrieved
from this bank. Selected patients had received a first cadaveric
kidney graft and were devoid of past medical history of autoimmune
disease. In all, 31 sera were obtained at various time points after
transplantation (2–12 years) from patients without chronic rejection
(that is, stable renal function for 42 years) and 32 sera were
obtained from patients at the time of the diagnosis of chronic
rejection.
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Control tissues. Fresh normal renal tissue was obtained from
the intact portion of six kidneys removed for renal cancer. Frozen
lymphoid tissues were obtained from normal lymph nodes (n¼ 12)
harvested during surgery.
All the patients gave informed consent for the use of the samples
for research purposes.
Histopathology
The renal cortex was dissected and embedded in paraffin, or snap-
frozen immediately in optimal cutting temperature medium
(Tissue-Tek, Agar Scientific, Stansted, Essex, UK) in liquid nitrogen.
Cryosections, 10 mm thick, and paraffin sections, 4 mm thick,
were used.
Routine examination was performed after Masson’s trichrome,
hematoxylin–eosin–safran, periodic acid-Schiff, and Silver staining.
Staging of the histopathological lesions was performed by a
trained renal pathologist (NP) using the Banff classification.
Indirect immunoperoxidase staining was performed with the
following primary antibodies (Abs): rabbit anti-human CD3e
(polyclonal, Abcam, Paris, France), mouse anti-human CD20 (clone
L26, Dako, Trappes, France), mouse anti-human follicular dendritic
cells (clone CNA.42, Dako), rat anti-human peripheral lymph node
addressin (clone MECA 79, BD Pharmingen, San Diego, CA), rabbit
anti-human podoplanin (polyclonal, Sigma-Aldrich, St Louis, MO),
mouse anti-human CD208/DC-LAMP (clone 104.G4, Beckman
Coulter, Fullerton, CA), mouse anti-human-CD138 (clone B-A38,
Serotec, Oxford, UK), and rat anti-human BAFF antibody (BLyS,
CD257; 1:300; clone buffy-2; Abcam). The first primary Ab was
applied, followed by incubation with the appropriate biotinylated
secondary Abs and with streptavidin peroxidase and 3,3-diamino-
benzidine-tetrachloride (ChemMate detection Kit, Dako). Negative
staining control experiments were conducted by omitting the
primary Ab.
Slides were counterstained with hematoxylin and eosin (Dako).
Flow cytometry
The renal cortex of fresh explanted grafts was cut with a sterile razor
blade into small fragments, which were incubated in a solution of
1mg/ml collagenase A and 0.1mg/ml DNAse I (Roche, Meylan,
France) for 1 h at 37 1C. Cell suspensions were passed through a
70-mm cell strainer, and mononuclear cells were separated over
Ficoll-Paque Plus (GE Healthcare, Piscataway, NJ).
A total of 10 million cells were incubated with one of the
following fluorescent monoclonal Ab cocktails specific for human
cell surface markers: (1) CD3 (PE-Texas Red, clone 7D6) and CD19
(FITC, clone SJ25C1); or (2i) CD3 (PE-Texas Red, clone 7D6),
CD4 (Alexa Fluor 700, clone RTPA-T4), CD8 (Pacific blue, clone
RPA-T8), CD45RA (FITC, clone HI100), and CD45RO (PE, clone
UCHL1); or (3) CD3 (PE-Texas Red, clone 7D6), CD4 (Alexa Fluor
700, clone RTPA-T4), CD8 (Pacific blue, RPA-T8), and OX40
(CD134, FITC, clone ACT35); or (4) CD3 (PE-Texas Red, clone
7D6), CD4 (Alexa Fluor 700, clone RTPA-T4), CD25 (APC, clone
M-A251) and, following fixation and permeabilization of the cells,
Foxp3 (PE, 259D/C7). All these Abs were obtained from BD
Biosciences (San Jose, CA), except the anti-CD3 that was obtained
from Caltag Laboratories (Burlingame, CA).
More than 1.106 events in the lymphoid forward scatter/side
scatter gate were acquired on an LSRII flow cytometer (BD
Biosciences) and analyzed with the FlowJo software (Tree Star,
Ashland, OR).
Tissue culture
The renal cortex of fresh explanted allografts was dissected and cut
with a sterile razor blade into B0.5mm3 fragments. A total of 24
tissue fragments were randomly selected, washed three times in cold
RPMI-1640 medium (Cambrex, Walkersville, MD), and then placed
individually in the well of a 24-well plate in 1ml of fresh medium
supplemented with 100U/ml penicillin/streptomycin and 25 mg/ml
Fungizone (Gibco, Cergy Pontoise, France). The plate was then
incubated at 37 1C in 5% CO2. After 5 days of culture, the
supernatants were harvested, centrifuged at 2000 r.p.m. for 10min,
and stored at 20 1C until further analysis.
Autoantibody detection
HEp2 cell assay. HEp2 is a cell line established from HeLa,
which is routinely used for the detection of antibodies directed
against intracellular antigens in human autoimmune disease. The
commercial Kallestad kit was used in accordance with the
instructions of the manufacturer (Bio-Rad, Marnes-la-Coquette,
France). The serum of each patient was diluted (1/100) in
phosphate-buffered saline (PBS) and tissue culture supernatant
was used pure. The samples were incubated on HEp2 cells fixed on
glass slides in a moisture chamber for 30min at room temperature.
After three washes in PBS, the slides were incubated with a goat
anti-human IgG (F(ab0)2) conjugated to fluorescein isothio-
cyanate (diluted 1/100 in PBS; Bio-Rad) for 30min at room
temperature. Subsequently, the slides were washed three times in
PBS for 5min and mounted in 70% glycerol. The slides were
examined using an Olympus fluorescence microscope (Southend-
on-Sea, UK). Two independent visual analyses were performed for
each sample by the same trained immunobiologist (NF). The
different nuclear immunofluorescence patterns were noted: homo-
geneous, speckled, nucleolar proteins of the mitotic apparatus. The
cytoplasmic patterns were also considered.
Indirect immunofluorescence on rat and monkey frozen tissue
sections. Indirect immunofluorescence on cryostat sections of rat
kidney, stomach, and liver (Bio-Rad), or monkey kidney (Bio-Rad)
was used to assess the presence of autoantibodies directed against
tissue autoantigens.29 Briefly, tissue culture supernatants were
incubated undiluted for 30min at room temperature with the
sections. Bound antibodies were detected with a goat anti-human
IgG (F(ab0)2) conjugated to fluorescein isothiocyanate (diluted
1/100 in PBS; Bio-Rad). The slides were subsequently washed three
times in PBS for 5min and mounted in 70% glycerol. The analysis
was performed by a trained immunobiologist (NF).
Cytokine dosage
Concentrations of tumor necrosis factor-a, IL-1b, IL-6, transform-
ing growth factor-b, interferon-g, IL-4, IL-17, and IL-21 were
measured in the tissue culture supernatants using specific enzyme-
linked immunosorbent assay kits (eBioscience, Paris, France),
according to the manufacturer’s instructions.
Molecular biology
mRNA extraction and reverse transcription. Total RNA
was isolated from the renal and lymphoid tissues using the RNeasy
Mini Kit (Qiagen, Courtaboeuf, France). cDNAs were generated
from 1 mg of total RNA using SuperScript II reverse transcriptase
(Invitrogen, Cergy Pontoise, France) and random decamers
(ABgene, Brumath, France).
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Primer design. The following gene-specific primer sets were
used: BAFF 50-CCTCACGGTGGTGTCTTTCT-30, 50-AAAGCTGAG
AAGCCATGGAA-30; GAPDH 50-GTGAAGGTCGGAGTCAAC-30,
50-GGTGAAGACGCCAGTGGACTC-30. All the primers were
designed using the Primer3 software (http://primer3.sourceforge.
net/) and obtained from Eurogentec (Angers, France).
Real-time quantitative PCR. Real-time quantitative PCR was
performed on an ABI Prism 7300 sequence detection system
(Applied Biosystems, Carlsbad, CA) in a total volume of 24 ml,
containing 4 ml of cDNA sample, 8 ml of diluted primer set, and 12 ml
of SYBR Green Master Mix (Qiagen). The thermal cycling was
carried out by starting at 95 1C for a 10-min hold, followed by 50
amplification cycles at 95 1C for 15 s and at 60 1C for 60 s.
Dissociation curve analysis was performed at the end of 50 cycles
to verify the identity of the PCR product. No signals were detected
in no-template controls. Results are expressed as threshold cycle (Ct)
values corresponding to the cycle at which PCR enters the
exponential phase and were normalized to the Ct value obtained
with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) house-
keeping gene amplification.
Statistical analysis
The data were analyzed using the JMP 6.0 software (SAS Institute,
Cary, NC). The w2 test was used to compare categorical variables
and Mann–Whitney U-test for comparisons of continuous and
ordinal scale variables. The P-values of o0.05 were considered
statistically significant.
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